RGNT on NYSE
REGENTIS BIOMATERIALS LTD.
GelrinC, we aim to bring to market a product for the therapy of an unmet need for the large market of cartilage injuries in the knee.4 From its latest annual report
Price unavailable
Last updated Oct 19, 2026.
Overview
- TickerRGNT on NYSE1
- IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies1
- HeadquartersL31
- Incorporated inIsrael3
- Business address12 Ha'Ilan Street, Northern Industrial, Zone, P.O. Box 260, Or Akiva3
- Filer categoryNon-accelerated filer, Emerging growth company3
- Legal formCorporation
See how the biggest companies compare on our leaderboards
GelrinC, we aim to bring to market a product for the therapy of an unmet need for the large market of cartilage injuries in the knee.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Financial statements
No quarterly figures reported.
Every line of the income statement as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Horizon 2020 grant | $2.3M | ||
| Research and development expenses | -$331.0K | -$662.0K | -$806.0K |
| Research and development expenses, net | -$331.0K | $1.6M | -$806.0K |
| General and administrative expenses | -$6.6M | -$712.0K | -$1.1M |
| Operating profit (loss) | -$7.0M | $932.0K | -$1.9M |
| Change in fair value of convertible notes | -$4.9M | $3.5M | -$2.0M |
| Changes in fair value of warrant liability | $160.0K | $463.0K | $62.0K |
| Other financing expense, net | -$1.9M | -$77.0K | -$244.0K |
| Financial income (expense), net | -$6.7M | $3.9M | -$2.2M |
| Net income (loss) and comprehensive income (loss) | -$13.6M | $4.8M | -$4.1M |
| Basic net income (loss) per share | -$24.16 | $1.72 | -$24.09 |
| Dilutednet income (loss) per share | -$24.16 | $1.72 | -$24.09 |
| Weighted average number of ordinary shares used in computing basic | 566.7K shares | 2.8M shares | 173.5K shares |
| Weighted average number of ordinary shares used in computing diluted | 566.7K shares | 2.8M shares | 173.5K shares |
No quarter-by-quarter statement was filed.
No quarterly figures reported.
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 6 quarters (quarterly), latest first.2
| Period ending | 2025-12-31 | 2025-03-31 | 2024-12-31 | 2023-12-31 | 2023-08-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $7.4M | $229.0K | |||
| Other current assets | $240.0K | $253.0K | |||
| Total assets | $7.6M | $482.0K | |||
| Trade accounts payable | $266.0K | $252.0K | |||
| Other accounts payable | $1.4M | $1.1M | |||
| Short-term loans | $1.2M | $573.0K | $210.0K | $325.0K | |
| Convertible notes | $4.4M | ||||
| Warrant liability | $160.0K | ||||
| Total current liabilities | $2.9M | $6.5M | |||
| Total liabilities | $2.9M | $6.5M | |||
| Total temporary equity | $35.1M | ||||
| Additional paid-in capital | $60.5M | $1.0M | |||
| Accumulated deficit | -$55.8M | -$42.1M | |||
| Total shareholders equity (deficit) | $4.7M | -$41.1M | -$45.9M | ||
| Total liabilities, temporary equity and shareholders equity (deficit) | $7.6M | $482.0K | |||
| Ordinary shares, shares authorized | 22.5M shares | 22.5M shares | 19.7M shares | ||
| Ordinary shares, shares issued | 5.2M shares | 162.2K shares | |||
| Ordinary shares, shares outstanding | 5.2M shares | 162.2K shares |
| Period ending | 2025-12-31 | 2025-03-31 | 2024-12-31 | 2023-12-31 | 2023-08-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | $7.4M | $229.0K | ||||
| Other current assets | $240.0K | $253.0K | ||||
| Total assets | $7.6M | $482.0K | ||||
| Trade accounts payable | $266.0K | $252.0K | ||||
| Other accounts payable | $1.4M | $1.1M | ||||
| Short-term loans | $1.2M | $573.0K | $210.0K | $325.0K | ||
| Convertible notes | $4.4M | |||||
| Warrant liability | $160.0K | |||||
| Total current liabilities | $2.9M | $6.5M | ||||
| Total liabilities | $2.9M | $6.5M | ||||
| Total temporary equity | $35.1M | |||||
| Additional paid-in capital | $60.5M | $1.0M | ||||
| Accumulated deficit | -$55.8M | -$42.1M | ||||
| Total shareholders equity (deficit) | $4.7M | -$41.1M | -$45.9M | -$42.1M | ||
| Total liabilities, temporary equity and shareholders equity (deficit) | $7.6M | $482.0K | ||||
| Ordinary shares, shares authorized | 22.5M shares | 22.5M shares | 19.7M shares | |||
| Ordinary shares, shares issued | 5.2M shares | 162.2K shares | ||||
| Ordinary shares, shares outstanding | 5.2M shares | 162.2K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income (loss) | -$13.6M | $4.8M | -$4.1M |
| Change in fair value of convertible notes | $4.9M | -$3.5M | $2.0M |
| Share based payment | $7.0M | ||
| Exchange rate differences on grant liability | -$68.0K | $73.0K | |
| Change in fair value of warrant liability | -$160.0K | -$463.0K | -$62.0K |
| Amortization of the discount on short-term loans | $245.0K | $161.0K | $173.0K |
| Interest expense on short-term loans | $79.0K | $10.0K | |
| Other current assets | -$163.0K | -$238.0K | $462.0K |
| Trade accounts payable | $14.0K | -$101.0K | $147.0K |
| Other accounts payable | $280.0K | -$1.3M | $100.0K |
| Net cash used in operating activities | -$1.4M | -$641.0K | -$1.2M |
| Issuance of ordinary shares and warrants in an initial public offering, net (see Note 11) | $8.2M | ||
| Repayment of short-term loan | -$325.0K | ||
| Proceeds from issuance of convertible notes | $450.0K | ||
| Proceeds from short-term loans | $300.0K | $400.0K | $325.0K |
| Net cash provided by financing activities | $8.5M | $525.0K | $325.0K |
| Net change in cash and cash equivalents | $7.1M | -$116.0K | -$895.0K |
| Conversion of convertible notes into ordinary shares | $9.3M | $1.1M | |
| Conversion of accrued payroll salary into short-term loan (see Note 5) | $117.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led REGENTIS BIOMATERIALS LTD., and when. Pick a name to see everywhere that person has worked.
- Chief executive officerEhud Geller Mar 18, 2026 to now5
- Chief financial officerOri Gon Mar 18, 2026 to now6
Board members and other officers (8)
- Chief Accounting OfficerArie Gordashnikov Mar 18, 2026 to now7
- Chief Medical OfficerGalit Reske Mar 30, 2026 to now8
- Board memberEfraim Cohen-Arazi Mar 18, 2026 to now9
- Board memberEhud Geller Mar 18, 2026 to now5
- Board memberJeff Dykan Mar 18, 2026 to now10
- Board memberKeith Valentine Mar 18, 2026 to now11
- Board memberPini Ben-Elazar Mar 18, 2026 to now12
- Board memberSusan Alpert Phd. Md. Mar 18, 2026 to now13
Timeline
- Mar 18, 2026New chief executive Ehud Geller becomes CEO5
Filings
93 filings to the SEC since October 2021: 2 annual reports, 15 insider forms, 2 large holders, 1 private raises, 73 other. The latest 20:
- Oct 13, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Sep 22, 2026EFFECT EDGAR
- Sep 17, 2026POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-1 EDGAR
- Sep 11, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Aug 13, 2026SCHEDULE 13G EDGAR
- Aug 11, 2026S-8 REGISTRATION STATEMENT EDGAR
- Jul 20, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 15, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 13, 2026EFFECT EDGAR
- Jul 13, 20264 EDGAR
- Jul 13, 2026424B3 PROSPECTUS EDGAR
- Jul 13, 20264 EDGAR
- Jul 13, 20264 EDGAR
- Jul 13, 20264 EDGAR
- Jul 13, 20264 EDGAR
- Jul 13, 20264 EDGAR
- Jul 9, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 8, 2026F-1 REGISTRATION STATEMENT EDGAR
- Jul 2, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jun 25, 2026D EDGAR
The 93 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Rosalind Advisors, Inc.SCHEDULE 13G, 1 filing Aug 13, 202614
- Ehud GellerSCHEDULE 13G, 1 filing Feb 17, 202615
Money raised
Private offerings the company reported to the SEC on Form D.
- Jun 17, 2026Raised $6.5 million in a private offering of equity Form D: 22 investors so far Form D
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5SEC EDGAREhud Geller, Chief executive officer
- 6SEC EDGAROri Gon, Chief financial officer
- 7
- 8SEC EDGARGalit Reske, Chief Medical Officer
- 9SEC EDGAREfraim Cohen-Arazi, Board member
- 10SEC EDGARJeff Dykan, Board member
- 11SEC EDGARKeith Valentine, Board member
- 12SEC EDGARPini Ben-Elazar, Board member
- 13SEC EDGARSusan Alpert Phd. Md., Board member
- 14
- 15